Bromocriptine treatment for perseveration in demented patients

Area of Science:

• Neuroscience
• Pharmacology
• Geriatric Medicine

Background:

• Behavioral perseveration in dementia may stem from disrupted neurotransmitter systems, particularly dopaminergic pathways.
• Understanding the neurobiological underpinnings of perseveration is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the efficacy of a dopamine agonist, bromocriptine, in treating perseveration in patients with dementia.
• To assess the impact of bromocriptine on specific types of perseveration and overall cognitive function.

Main Methods:

• An open-label trial involving eight patients diagnosed with ischemic vascular or degenerative dementia.
• A 25-day treatment regimen with bromocriptine, with a maximum daily dose of 10 mg.
• Assessment using neuropsychological scales and a specialized test battery for perseveration.

Main Results:

• Significant improvement was observed in recurrent and stuck-in-set types of perseveration.
• No significant changes were noted in measures of general attention or overall cognitive function.
• The findings suggest bromocriptine may ameliorate frontal lobe functions supporting focused attention and working memory.

Conclusions:

• Bromocriptine shows promise as a pharmacotherapy for treating perseveration in dementia patients.
• The results support the hypothesis that dopaminergic system supplementation can improve specific behavioral symptoms.
• Further investigation with a double-blind, placebo-controlled study is recommended due to the preliminary nature and small sample size.